This post was originally published on this site
Operating profit, adjusted for special items, rose 10% to $4.47 billion, driven by higher sales of arthritis and psoriasis drug Cosentyx and heart failure treatment Entresto.
In a statement on Tuesday, Novartis said it increased its peak sales guidance for Cosentyx to at least $7 billion and for Entresto to at least $5.0 billion.
